A Study of the SMART Stent in the Treatment SFA Disease. (SIROCCO)
Primary Purpose
Peripheral Artery Disease
Status
Completed
Phase
Phase 2
Locations
Germany
Study Type
Interventional
Intervention
drug-eluting stent
bare-metal stent
Sponsored by
About this trial
This is an interventional treatment trial for Peripheral Artery Disease
Eligibility Criteria
Inclusion Criteria: One superficial femoral artery presenting > 70% stenosis(es) or total occlusion Symptomatic leg ischemia by Rutherford Classification (category 1, 2, 3 or 4) Exclusion Criteria: Tissue loss due to ischemic disease (Rutherford category 5 or 6). Tandem lesion requiring non overlapping stents;
Sites / Locations
- University Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
1
2
Arm Description
Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
SMART™ bare-metal stent
Outcomes
Primary Outcome Measures
In-stent mean lumen diameter percent stenosis via quantitative angiography.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00232869
Brief Title
A Study of the SMART Stent in the Treatment SFA Disease.
Acronym
SIROCCO
Official Title
A Clinical Investigation of the SIROlimus Coated Cordis SMART™ Nitinol Selfexpandable Stent for the Treatment of Obstructive Superficial Femoral Artery Disease.
Study Type
Interventional
2. Study Status
Record Verification Date
February 2010
Overall Recruitment Status
Completed
Study Start Date
February 2001 (undefined)
Primary Completion Date
June 2003 (Actual)
Study Completion Date
May 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Cordis Corporation
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The main objective of this study is to assess the safety and performance of the sirolimus coated Cordis SMART™ nitinol self expandable stent device and its delivery system in the treatment of obstructive superficial femoral artery (SFA) disease in reducing percent in-stent mean lumen diameter stenosis in de novo or restenotic native lesions as compared to the uncoated SMART™ stent.
Detailed Description
This is a multi-center, prospective, randomized, double blind, two-arm feasibility study evaluating the safety and performance of the sirolimus coated Cordis SMART™ nitinol self-expanding stent and delivery system as compared to the uncoated SMART™ stent and delivery system. It is anticipated that a total of 90 patients will be entered into the study. Patients will be randomized on a 1:1 basis of coated to uncoated stents.
Ninety (90) patients with de novo or restenotic native SFA lesions will be randomized to the Sirolimus Coated SMART™ nitinol self-expanding stent or to the uncoated (bare) SMART™ stent.
Patients will be followed for 24 months post-procedure, with all patients having duplex ultrasound and clinical assessments at discharge, 1, 6, 9, 18 and 24 months, angiography at 6 six months and plain X-ray at 18 months. This study will be conducted at nine investigational sites. (Protocol was amended where 56 additional patients were recruited and followed for up to 5 years.)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Artery Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
93 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
Arm Title
2
Arm Type
Active Comparator
Arm Description
SMART™ bare-metal stent
Intervention Type
Device
Intervention Name(s)
drug-eluting stent
Intervention Description
Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
Intervention Type
Device
Intervention Name(s)
bare-metal stent
Intervention Description
SMART™ bare-metal stent
Primary Outcome Measure Information:
Title
In-stent mean lumen diameter percent stenosis via quantitative angiography.
Time Frame
6 months.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
One superficial femoral artery presenting > 70% stenosis(es) or total occlusion
Symptomatic leg ischemia by Rutherford Classification (category 1, 2, 3 or 4)
Exclusion Criteria:
Tissue loss due to ischemic disease (Rutherford category 5 or 6).
Tandem lesion requiring non overlapping stents;
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stephan H Duda, MD
Organizational Affiliation
Tübingen - Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital
City
Tübingen
ZIP/Postal Code
72070
Country
Germany
12. IPD Sharing Statement
Citations:
PubMed Identifier
17154704
Citation
Duda SH, Bosiers M, Lammer J, Scheinert D, Zeller T, Oliva V, Tielbeek A, Anderson J, Wiesinger B, Tepe G, Lansky A, Jaff MR, Mudde C, Tielemans H, Beregi JP. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006 Dec;13(6):701-10. doi: 10.1583/05-1704.1.
Results Reference
result
Learn more about this trial
A Study of the SMART Stent in the Treatment SFA Disease.
We'll reach out to this number within 24 hrs